167 related articles for article (PubMed ID: 18922853)
21. High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects.
Yong AS; Rezvani K; Savani BN; Eniafe R; Mielke S; Goldman JM; Barrett AJ
Blood; 2007 Jul; 110(2):770-5. PubMed ID: 17412886
[TBL] [Abstract][Full Text] [Related]
22. Leukemic target susceptibility to natural killer cytotoxicity: relationship with BCR-ABL expression.
Baron F; Turhan AG; Giron-Michel J; Azzarone B; Bentires-Alj M; Bours V; Bourhis JH; Chouaib S; Caignard A
Blood; 2002 Mar; 99(6):2107-13. PubMed ID: 11877286
[TBL] [Abstract][Full Text] [Related]
23. NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
Chang MC; Cheng HI; Hsu K; Hsu YN; Kao CW; Chang YF; Lim KH; Chen CG
Front Immunol; 2018; 9():3152. PubMed ID: 30705677
[TBL] [Abstract][Full Text] [Related]
24. Altered phenotype of natural killer cell subsets after haploidentical stem cell transplantation.
Schulze A; Schirutschke H; Oelschlägel U; Schmitz M; Füssel M; Wassmuth R; Ehninger G; Bornhäuser M; Platzbecker U
Exp Hematol; 2008 Apr; 36(4):378-89. PubMed ID: 18261840
[TBL] [Abstract][Full Text] [Related]
25. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
Sahin U; Dalva K; Gungor F; Ustun C; Beksac M
Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
[TBL] [Abstract][Full Text] [Related]
26. Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia.
Hauch M; Gazzola MV; Small T; Bordignon C; Barnett L; Cunningham I; Castro-Malaspinia H; O'Reilly RJ; Keever CA
Blood; 1990 Jun; 75(11):2250-62. PubMed ID: 2189508
[TBL] [Abstract][Full Text] [Related]
27. Transcriptional analysis of quiescent and proliferating CD34+ human hemopoietic cells from normal and chronic myeloid leukemia sources.
Graham SM; Vass JK; Holyoake TL; Graham GJ
Stem Cells; 2007 Dec; 25(12):3111-20. PubMed ID: 17717066
[TBL] [Abstract][Full Text] [Related]
28. The effect of Bcr-Abl protein tyrosine kinase on maturation and proliferation of primitive haematopoietic cells.
Buckle AM; Mottram R; Pierce A; Lucas GS; Russell N; Miyan JA; Whetton AD
Mol Med; 2000 Oct; 6(10):892-902. PubMed ID: 11126203
[TBL] [Abstract][Full Text] [Related]
29. Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1.
Bosman MC; Schuringa JJ; Quax WJ; Vellenga E
Exp Hematol; 2013 Jun; 41(6):530-538.e1. PubMed ID: 23416210
[TBL] [Abstract][Full Text] [Related]
30. The sensitivity of chronic myeloid leukemia CD34 cells to Bcr-Abl tyrosine kinase inhibitors is modulated by ceramide levels.
Wang J; Hu J; Jin Z; Wan H
Leuk Res; 2016 Aug; 47():32-40. PubMed ID: 27244255
[TBL] [Abstract][Full Text] [Related]
31. The Aryl Hydrocarbon Receptor Antagonist StemRegenin1 Improves In Vitro Generation of Highly Functional Natural Killer Cells from CD34(+) Hematopoietic Stem and Progenitor Cells.
Roeven MW; Thordardottir S; Kohela A; Maas F; Preijers F; Jansen JH; Blijlevens NM; Cany J; Schaap N; Dolstra H
Stem Cells Dev; 2015 Dec; 24(24):2886-98. PubMed ID: 26414401
[TBL] [Abstract][Full Text] [Related]
32. Transplantation of highly purified HLA-identical sibling donor peripheral blood CD34+ cells without prophylactic post-transplant immunosuppression in adult patients with first chronic phase chronic myeloid leukemia: results of a phase II study.
Beelen DW; Peceny R; Elmaagacli A; Ottinger H; Kummer G; Opalka B; Seeber S; Schaefer UW
Bone Marrow Transplant; 2000 Oct; 26(8):823-9. PubMed ID: 11081380
[TBL] [Abstract][Full Text] [Related]
33. [Effect of bortezomib on reverse multidrug resistance and XIAP expression in imatinib-resistant primary cells of chronic myeloid leukemia in blastic crisis].
Zhao J; Ma LM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):899-904. PubMed ID: 23998582
[TBL] [Abstract][Full Text] [Related]
34. BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia.
Boissel N; Rea D; Tieng V; Dulphy N; Brun M; Cayuela JM; Rousselot P; Tamouza R; Le Bouteiller P; Mahon FX; Steinle A; Charron D; Dombret H; Toubert A
J Immunol; 2006 Apr; 176(8):5108-16. PubMed ID: 16585609
[TBL] [Abstract][Full Text] [Related]
35. Role of BCR-ABL-Y177-mediated p27kip1 phosphorylation and cytoplasmic localization in enhanced proliferation of chronic myeloid leukemia progenitors.
Chu S; McDonald T; Bhatia R
Leukemia; 2010 Apr; 24(4):779-87. PubMed ID: 20200561
[TBL] [Abstract][Full Text] [Related]
36. [STI571 enhances the effect of arsenic trioxide and Velcade on bcr/abl+-CD34+ cell proliferation and apoptosis].
Li CY; Meng FY; Sun QX; Fu YB; Li L; Yi ZS; Song LL
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Nov; 27(11):1665-9. PubMed ID: 18024285
[TBL] [Abstract][Full Text] [Related]
37. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
Chu S; Holtz M; Gupta M; Bhatia R
Blood; 2004 Apr; 103(8):3167-74. PubMed ID: 15070699
[TBL] [Abstract][Full Text] [Related]
38. Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli.
Holtz MS; Forman SJ; Bhatia R
Leukemia; 2005 Jun; 19(6):1034-41. PubMed ID: 15815728
[TBL] [Abstract][Full Text] [Related]
39. Gene expression profile of circulating CD34(+) cells and granulocytes in chronic myeloid leukemia.
Čokić VP; Mojsilović S; Jauković A; Kraguljac-Kurtović N; Mojsilović S; Šefer D; Mitrović Ajtić O; Milošević V; Bogdanović A; Đikić D; Milenković P; Puri RK
Blood Cells Mol Dis; 2015 Dec; 55(4):373-81. PubMed ID: 26460262
[TBL] [Abstract][Full Text] [Related]
40. Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?
Goldman J; Gordon M
Leuk Lymphoma; 2006 Jan; 47(1):1-7. PubMed ID: 16321820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
